David Coman, Science 37 CEO

Sci­ence 37 takes the SPAC short­cut to Nas­daq, land­ing a $235M wind­fall for its push on de­cen­tral­ized tri­als

Sci­ence 37, which bills it­self as a pi­o­neer in the move to de­cen­tral­ized clin­i­cal tri­als, has reached the end of the SPAC trail to Nas­daq.

The life sci com­pa­ny has com­plet­ed its merg­er with LifeSci Ac­qui­si­tion II Corp., a blank check com­pa­ny, that will de­liv­er a $235 mil­lion bonus of cash, less the usu­al slate of fees.

De­cen­tral­ized tri­als have been all the rage in bio­phar­ma, par­tic­u­lar­ly dur­ing the pan­dem­ic as com­pa­nies ad­just­ed to lock­downs and dis­tanc­ing de­mands. But they were trendy even be­fore Covid made them ab­solute­ly nec­es­sary as drug de­vel­op­ers looked for new and bet­ter ways to at­tract a di­verse set of pa­tients for clin­i­cal stud­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.